Entasis Therapeutics Holdings, Inc.

Entasis Therapeutics Holdings, Inc.

Entasis Therapeutics Holdings, Inc.

Overview
Date Founded

2018

Headquarters

35 Gatehouse Park Drive,Waltham, MA 02451

Type of Company

Public

Employees (Worldwide)

47

Industries

Biotechnology

Company Description

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Contact Data
Trying to get in touch with decision makers at Entasis Therapeutics Holdings, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

General Counsel

Chief Development Officer

Chief Scientific Officer

Chief Medical Officer

Chief Financial Officer, Principal Accounting Officer & Chief Business Officer

Director-Business Development

Board of Directors

President & Chief Executive Officer-Fergene at Ferring Pharmaceuticals, Inc.

Managing Partner at Pivotal Bioventure Partners Investment Advisor LLC

Chief Financial & Accounting Officer at Arbutus Biopharma Corp.

President, Chief Executive Officer & Director at Entasis Therapeutics Holdings, Inc.

Research Associate at University of Michigan

Executive Vice President & Head of Research & Development at Ipsen SA

Paths to Entasis Therapeutics Holdings, Inc.
Potential Connections via
Relationship Science
You
Entasis Therapeutics Holdings, Inc.
Owners & Shareholders
Details Hidden

Pivotal Bioventure Partners seeks invests in companies located in the US and Europe. The firm target companies operating in the fields of biotechnology, innovative therapeutic products. It provide financing for seed, early and later-stage capital requirements.

Details Hidden

Pivotal Bioventure Partners seeks invests in companies located in the US and Europe. The firm target companies operating in the fields of biotechnology, innovative therapeutic products. It provide financing for seed, early and later-stage capital requirements.

Recent Transactions
Details Hidden

Entasis Therapeutics Holdings, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onEntasis Therapeutics Holdings, Inc. issued USD Common Stock

Escrow Agent

Advised onEntasis Therapeutics Holdings, Inc. issued USD Common Stock

Underwriter

Advised onEntasis Therapeutics Holdings, Inc. issued USD Common Stock

Associate

Advised onEntasis Therapeutics Holdings, Inc. issued USD Common Stock

Legal Advisor

Advised onEntasis Therapeutics Holdings, Inc. issued USD Common Stock

Legal Advisor

Advised onEntasis Therapeutics Holdings, Inc. issued USD Common Stock

Clients

Zai Lab Ltd. is a biopharmaceutical company. It engages in the discovering, licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need in the fields of oncology, infectious, and autoimmune diseases. The firm's products include Zejula and Optune. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Key Stats and Financials As of 2019
Market Capitalization
$122M
Total Enterprise Value
$26.2M
Earnings Per Share
$-3.33
Debt TEV
0.07x
TEVNet Income
-0.6x
Enterprise Value / Sales
3.75x
Total Equity
$42.2M
Total Debt
$1.83M
EBITDAMargin
-668.49%
EBITDA
$-46.8M
Net Profit
$-43.8M
Revenue
$7M
Investors
Details Hidden

Pivotal Bioventure Partners seeks invests in companies located in the US and Europe. The firm target companies operating in the fields of biotechnology, innovative therapeutic products. It provide financing for seed, early and later-stage capital requirements.

Details Hidden

TPG Biotech is a life science venture capital platform of TPG Capital. TPG Biotech focuses on therapeutics, medical devices, and healthcare services. By leveraging TPG's global network to support portfolio companies, TPG Biotech provides access to opportunities and operational experts from other platforms. They target investments globally with a particular focus on opportunities in North America & Asia Pacific, and provides financing for early & later stage capital requirements.

Details Hidden

Novo Ventures is an active manager which provides funding for early and later-stage capital requirements, and provides management support. The firm invests in both public and private companies from Northern Europe and the United States. Novo Ventures targets companies operating in the health technology and health services sector, and industries such as biotechnology and medical specialties. It looks to take minority stake positions in its investments, as well as a seat on the board.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Melinta Therapeutics, Inc. Pharmaceuticals - New Haven, CT

Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in Morristown, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Entasis Therapeutics Holdings, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Entasis Therapeutics Holdings, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Entasis Therapeutics Holdings, Inc..